No annual revenue total was found in Biomea Fusion, Inc.'s SEC filings.
Biomea Fusion, Inc. (BMEA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $34.8 million in cash and investments and $877,000 in total debt.
Revenue
—
Net income (TTM)
$-71.22M
Operating cash flow (TTM)
$-47.19M
+52.9% vs year-ago TTM
Free cash flow
$-120.26M
-20.3% vs prior year
EPS
$-1.18
+69.2% vs prior year
Dividend per share
None
Shares outstanding
72.30M
+92.4% vs prior year
Net cash
$33.95M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMEA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Carlos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1840439
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$83.5M | -$144.1M | -$126.1M | -$83.6M | -$41.7M |
| Net income | -$61.8M | -$138.4M | -$117.3M | -$81.8M | -$41.6M |
| Diluted EPS | -$1.18 | -$3.83 | -$3.44 | -$2.80 | — |
| Operating cash flow | -$70.4M | -$119.9M | -$96.6M | -$62.4M | -$35.4M |
| Free cash flow | — | -$120.3M | -$100.0M | -$63.4M | -$38.6M |
| Total assets | $58.6M | $79.9M | $199.9M | $129.3M | $185.7M |
| Total liabilities | $29.0M | $28.4M | $30.7M | $20.8M | $6.9M |
| Stockholders' equity | $29.6M | $51.6M | $169.2M | $108.5M | $178.8M |
| Cash and investments | $55.8M | $114.3M | $351.3M | $113.0M | $175.4M |
| Total debt | $1.6M | $8.8M | $10.3M | $2.3M | $2.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K | Current report | Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
All 290 Biomea Fusion, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.